Steven Cohen Biotechnology

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
INCY Incyte Corp	$16.1B	$157 Million 0.43% of portfolio	2,369,300	Q3 2024 New
BGNE Bei Gene, Ltd.	$20.8B	$150 Million 0.41% of portfolio	667,166	Q3 2024 Added 74.93%
CRNX Crinetics Pharmaceuticals, Inc.	$1.96B	$118 Million 0.32% of portfolio	2,300,643	Q3 2024 Reduced 17.27%
COGT Cogent Biosciences, Inc.	$535M	$113 Million 0.31% of portfolio	10,470,398	Q2 2024 Reduced 30.13%
TECH Bio Techne Corp	$2.98B	$89.7 Million 0.25% of portfolio	1,122,527	Q3 2024 New
ASND Ascendis Pharma A/S	$7.35B	$74 Million 0.2% of portfolio	495,547	Q3 2024 New
XNCR Xencor Inc	$1.2B	$62.7 Million 0.17% of portfolio	3,120,229	Q3 2024 Added 147.29%
KROS Keros Therapeutics, Inc.	$271M	$55 Million 0.15% of portfolio	947,570	Q3 2024 Added 155.86%
SNDX Syndax Pharmaceuticals Inc	$735M	$53.5 Million 0.15% of portfolio	2,778,267	Q3 2024 Reduced 0.16%
CLDX Celldex Therapeutics, Inc.	$1.06B	$53.3 Million 0.15% of portfolio	1,568,708	Q3 2024 Reduced 19.05%
AXSM Axsome Therapeutics, Inc.	$4.02B	$48.8 Million 0.13% of portfolio	542,620	Q3 2024 Added 13.27%
OLMA Olema Pharmaceuticals, Inc.	$217M	$44 Million 0.12% of portfolio	3,687,374	Q3 2024 Added 14.8%
CDMO Avid Bioservices, Inc.	$770M	$43.4 Million 0.12% of portfolio	3,815,806	Q3 2024 Added 42.75%
CNTA Centessa Pharmaceuticals PLC	$1.4B	$43.4 Million 0.12% of portfolio	2,715,663	Q3 2024 Added 54.12%
BNTX Bio N Tech Se	$27.4B	$43 Million 0.12% of portfolio	361,993	Q3 2024 Reduced 21.6%
PCVX Vaxcyte, Inc.	$5.21B	$41.1 Million 0.11% of portfolio	359,796	Q3 2024 New
AKRO Akero Therapeutics, Inc.	$1.11B	$37.4 Million 0.1% of portfolio	1,303,323	Q3 2024 New
RCUS Arcus Biosciences, Inc.	$1.02B	$37.3 Million 0.1% of portfolio	2,437,073	Q3 2024 Added 32.89%
RARE Ultragenyx Pharmaceutical Inc.	$2.86B	$36.3 Million 0.1% of portfolio	653,660	Q3 2024 Added 21.1%
ANNX Annexon, Inc.	$202M	$31.5 Million 0.09% of portfolio	5,326,998	Q3 2024 Reduced 11.05%
JAZZ Jazz Pharmaceuticals PLC	$7.69B	$30 Million 0.08% of portfolio	268,783	Q3 2024 Added 47.67%
CRVS Corvus Pharmaceuticals, Inc.	$231M	$29.4 Million 0.08% of portfolio	5,562,729	Q3 2024 Reduced 6.74%
CYTK Cytokinetics Inc	$4.42B	$24.5 Million 0.07% of portfolio	464,010	Q3 2024 Added 23.79%
INSM Insmed Inc	$9.86B	$23 Million 0.06% of portfolio	315,151	Q3 2024 Reduced 63.28%
TERN Terns Pharmaceuticals, Inc.	$173M	$22.6 Million 0.06% of portfolio	2,707,515	Q3 2024 Added 0.64%
PTCT Ptc Therapeutics, Inc.	$3.08B	$21.4 Million 0.06% of portfolio	575,860	Q3 2024 Added 2,056.78%
BCYC Bicycle Therapeutics PLC	$403M	$20.4 Million 0.06% of portfolio	899,799	Q3 2024 Added 1,438.12%
URGN Uro Gen Pharma Ltd.	$240M	$19.1 Million 0.05% of portfolio	1,506,646	Q3 2024 Reduced 38.49%
JANX Janux Therapeutics, Inc.	$1.69B	$18 Million 0.05% of portfolio	395,875	Q3 2024 Added 190.17%
OCUL Ocular Therapeutix, Inc	$620M	$17.8 Million 0.05% of portfolio	2,040,620	Q3 2024 Reduced 24.61%
XENE Xenon Pharmaceuticals Inc.	$2.47B	$15.1 Million 0.04% of portfolio	383,290	Q3 2024 Reduced 20.48%
RPRX Royalty Pharma PLC	$13.5B	$14.9 Million 0.04% of portfolio	526,633	Q3 2024 New
BMRN Biomarin Pharmaceutical Inc	$11.4B	$13.9 Million 0.04% of portfolio	197,718	Q3 2024 New
FOLD Amicus Therapeutics, Inc.	$2.63B	$13.5 Million 0.04% of portfolio	1,266,900	Q3 2024 New
STRO Sutro Biopharma, Inc.	$96.5M	$10.4 Million 0.03% of portfolio	2,997,453	Q3 2024 Reduced 32.61%
DNLI Denali Therapeutics Inc.	$2.91B	$9.72 Million 0.03% of portfolio	333,530	Q3 2024 Reduced 68.33%
PTGX Protagonist Therapeutics, Inc	$1.79B	$9.66 Million 0.03% of portfolio	214,872	Q3 2024 Reduced 76.38%
RLAY Relay Therapeutics, Inc.	$519M	$9.55 Million 0.03% of portfolio	1,349,400	Q3 2024 New
LEGN Legend Biotech Corp	$5.26B	$9.52 Million 0.03% of portfolio	195,371	Q3 2024 Reduced 35.84%
DSGN Design Therapeutics, Inc.	$265M	$8.61 Million 0.02% of portfolio	1,600,740	Q3 2024 Added 61.56%
MRVI Maravai Lifesciences Holdings, Inc.	$601M	$8.53 Million 0.02% of portfolio	1,026,749	Q3 2024 Reduced 70.83%
SLN Silence Therapeutics PLC	$181M	$8.51 Million 0.02% of portfolio	467,800	Q3 2024 Added 219.32%
PHAT Phathom Pharmaceuticals, Inc.	$273M	$7.95 Million 0.02% of portfolio	439,816	Q3 2024 New
VERA Vera Therapeutics, Inc.	$886M	$7.58 Million 0.02% of portfolio	171,573	Q3 2024 Added 44.18%
IMNM Immunome Inc.	$120M	$6.88 Million 0.02% of portfolio	470,647	Q3 2024 Added 22.22%
CCCC C4 Therapeutics, Inc.	$189M	$6.85 Million 0.02% of portfolio	1,201,848	Q3 2024 Added 331.42%
VIGL Vigil Neuroscience, Inc.	$53.4M	$5.44 Million 0.01% of portfolio	1,600,000	Q3 2024 Added 7.74%
QURE Uni Qure N.V.	$664M	$4.82 Million 0.01% of portfolio	976,893	Q3 2024 Added 336.11%
SRPT Sarepta Therapeutics, Inc.	$10.3B	$4.6 Million 0.01% of portfolio	36,855	Q3 2024 Reduced 24.65%
THRD Third Harmonic Bio, Inc.	$229M	$4.33 Million 0.01% of portfolio	319,329	Q3 2024 New

Shares Options

Steven Cohen

Steven Cohen is the founder and CEO of Point72 Asset Management, a successful investment firm that uses technology and data-driven approaches to investing. Cohen is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Steven Cohen's portfolio

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account